MS Wrap-up: Rituximab and COVID-19 Risk, New App for Functional Impairment, and More
Here are some of the latest developments in multiple sclerosis (MS) from our sister publication, NeurologyLive®.
Related Articles
Vitamin D Supplementation Linked to Reduced In-Hospital, ICU Mortality in Patients With COPD
Vitamin D supplementation may decrease in-hospital and intensive care unit (ICU) mortality in patients with chronic obstructive pulmonary disease (COPD), a study found.
FDA Approves One-Time Gene Therapy Fidanacogene Elaparvovec for Hemophilia B
The FDA has approved fidanacogene elaparvovec-dzkt (Beqvez; Pfizer), a gene therapy administered in a one-time dose, for certain patients with moderate to severe hemophilia B.
What We’re Reading: Kaiser Permanente Data Breach; GSK Sues Pfizer, BioNTech; HIV Infections via Cosmetic Injections
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing…
Melatonin Fails to Ease Fatigue in Patients With Early-Stage Breast Cancer Undergoing Radiotherapy
Melatonin showed no benefit for cancer-related fatigue or other symptoms in women with early-stage breast cancer receiving radiotherapy treatment.
Dr Ryan Stice Shares Strategy on Expanding Access to Care With Virtual Population Health Teams
In an interview during The American Journal of Managed Care®’s Institute for Value-Based Medicine® event, held with Sutter Health, Ryan Stice, PharmD, BCPS, explains the…
Talquetamab Cost-Effective Breakthrough for RRMM
The FDA granted accelerated approval to talquetamab on August 9, 2023, as a treatment option for adult patients with relapsed/refractory multiple myeloma (RRMM) who have…
Optimizing BTK Inhibitors in CLL and SLL
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.
What We’re Reading: FTC Noncompete Ban Finalized; Unchecked Hospital Mergers Raised Health Costs; H5N1 Bird Flu Virus Particles Found
The Federal Trade Commission’s (FTC’s) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce;…
Dr Robert Zimmerman Discusses Challenges, Adverse Effects of GLP-1 and Multi-Agonist Therapies
Robert Zimmerman, MD, discussed the adverse side effects associated with glucagon-like peptide-1 (GLP1) and multi-agonist therapies, as well as explored the challenges in developing these…
Award-Winning Poster Presentations From AMCP 2024
At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more…